| Vol. 13.08 – 4 March, 2021 |
| |
|
|
| The authors revealed that SF3A3 protein levels predict molecular and phenotypic features of aggressive human breast cancers. [Molecular Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists report that low levels of TAp73 correlated with an increased NF-κB–regulated inflammatory signature in breast cancer. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors found that tektin4 loss sensitized triple-negative breast cancer cells, xenograft models, and patient-derived organoid models to the HDAC6-selective inhibitor ACY1215. [Oncogene] |
|
|
|
| In order to uncover metabolic pathways regulated by BCDIN3D in cancer, researchers performed an unbiased analysis of the metabolome, transcriptome, and proteome of breast cancer cells depleted for BCDIN3D. [Oncogene] |
|
|
|
| Investigators demonstrated that LAS1 like ribosome biogenesis factor protein expression was significantly elevated in TNBC patients, and it functionally was important for mammary tumor growth in xenograft models and enabled invasive attributes. [Cell Death & Disease] |
|
|
|
| Scientists investigated the interplay and networking pathways occurring between TGFβ family ligands in regulating stemness in TNBC. They found that TGFβ stimulation of TNBCs resulted in enhanced tumorsphere formation efficiency and an increased proportion of the highly tumorigenic CD44high/CD24low cancer stem cell population. [Oncogenesis] |
|
|
|
| Nimbolide inhibited cell proliferation, migratory, and invasive abilities of TNBC cells and also changed the shape of MDA-MB-231 cells, which is correlated with cytoskeletal changes including actin depolymerization. [Molecular Therapy-Oncolytics] |
|
|
|
| Researchers focused on terminal differentiation-induced non-coding RNA (TINCR) and explored its role in the pathogenesis of breast cancer. [Cell Death Discovery] |
|
|
|
| Scientists found that dual phosphoinositide 3-kinase and poly ADP-ribose polymerase inhibition with BKM120 and olaparib significantly reduced the proliferation of BRCA-proficient TNBC cell lines. [Scientific Reports] |
|
|
|
| The authors analyzed miRNA expression within areas of TNBCs with cellular morphology that may be related to the epithelial to mesenchymal transition process and discussed possible associations. [Scientific Reports] |
|
|
|
|
| Scientists discuss the breast tumor microbiota, its colonization by F. nucleatum, possible mechanisms by which F. nucleatum might promote breast cancer progression and how this might impact breast cancer treatment. [Immunology Letters] |
|
|
|
|
| Allarity Therapeutics A/S announced that it has enrolled the first patient in its European Phase II clinical trial of IXEMPRA® for the treatment of metastatic breast cancer. [Allarity Therapeutics A/S] |
|
|
|
| Kintara Therapeutics, Inc.announced the appointment of Mario Lacouture, to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer. [Kintara Therapeutics, Inc.] |
|
|
|
|
|
|
|
| Gilead Sciences, Inc. – Zug, Switzerland |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
| CyberCoders – San Diego, California, United States |
|
|
|
|